Latest Health News
WHO 2025 World Malaria Report: Progress but funding threatens gains
The WHO's 2025 World Malaria Report highlights expanded prevention—new-generation nets, malaria vaccine rollout and chemoprevention—while warning progress is at risk due to reduced funding and gaps in net and pregnancy prevention coverage.
Once‑weekly oral islatravir plus lenacapavir shows sustained HIV suppression
Phase 2 data report that a once‑weekly oral combination of islatravir and lenacapavir maintained HIV viral suppression through 48 weeks, offering a potential adherence‑friendly alternative to daily ART as larger phase 3 trials continue.
WHO and Germany commit €14 million to support health response in occupied Palestinian territory
The WHO and Germany signed a €14 million top‑up agreement to bolster emergency health services and humanitarian health response in the occupied Palestinian territory, enhancing supplies and coordination for affected populations.
ProMED reports multiple ongoing infectious disease alerts including Lassa fever and H5N1
ProMED's rapid alerts list recent events such as a Lassa fever update in Nigeria, HPAI H5N1 in Taiwan poultry, hantavirus reports in the Americas, and localized outbreaks of salmonellosis and legionellosis.
Rising projection of drug‑resistant bloodstream infections across Europe
A new study warns that bloodstream infections from drug‑resistant bacteria are expected to increase significantly across Europe in coming years, signalling growing AMR challenges for health systems.
FDA and gene/cell therapy milestones in 2025 expand treatment options
2025 saw multiple regulatory milestones: FDA approvals and designations including first‑ever Encelto for MacTel, AMT‑130 breakthrough therapy for Huntington’s, and RNAi expansion with Amvuttra approval for ATTR‑CM, marking rapid growth in gene, cell and RNA therapies.
Top FDA oncology approvals in 2025 broaden targeted cancer therapy landscape
The FDA approved several important oncology agents in 2025—such as sotorasib/panitumumab for KRAS G12C CRC and belzutifan for PPGL—reflecting advances in targeted and precision oncology options.
Medical physics and biotech breakthroughs in 2025: implants, proton arc therapy, vision restoration
Highlights from 2025 include the first carbon ion beam cancer experiment in Germany, clinical proton arc therapy in Italy, a wireless retinal implant restoring reading in AMD patients, and novel miniaturized implants and sensors in medical devices research.
MIT/Stanford work explains rare myocarditis after mRNA COVID vaccines and potential mitigation
Researchers at Stanford report mechanisms by which mRNA COVID vaccines can rarely trigger heart inflammation in young men and identify approaches that might reduce that risk, shedding light on vaccine safety optimization.
Innovations in cancer immunotherapy and in‑body 3D tissue printing draw attention
2025 biotech reports include advances making in‑body 3D printing (DISP) possible and promising CAR‑T and gene editing preclinical/early clinical results that could enable broader treatment of solid tumors and genetic diseases.
Global vaccine delivery milestone: Portugal reports 32 million COVID‑19 vaccinations over five years
Portugal reported delivering more than 32 million COVID‑19 vaccinations over five years, illustrating sustained national vaccine rollout and monitoring efforts.
Product approvals and updates for 2025 include new treatments for menopause, depression and more
Regulatory and product updates in December 2025 list approvals such as elinzanetant for vasomotor symptoms of menopause and lumateperone for depression, reflecting continued therapeutic diversification.